Cardiovascular disease (CVD) is a significant health care problem in the United States today. Women comprise an increasing component of the population affected by this disease. Recent reports have suggested that women are not enrolled in adequate numbers in major clinical studies and, furthermore, are less likely to receive treatment as recommended by evidence-based medicine guidelines. Historical differences in the investigation and treatment of cardiovascular disease between women and men are discussed. Reasons for differences in study enrollment of women are proposed. Efforts by the Food and Drug Administration to improve data collection in women are outlined. The influence of major risk factors, including smoking, hyperlipidemia, and hypertension, on development and progression of CVD is addressed. Major trials of CVD and heart failure are examined. An assessment of progress toward a goal of gender treatment equality is made.
Get full access to this article
View all access options for this article.
References
1.
1. US Department of Health and Human Services. Fact Book Fiscal Year 2001. Bethesda, Md: National Institutes of Health National Heart, Lung and Blood Institute ; 2002:10.
2.
2. US Census Bureau. Current Population Survey. Washington, DC: US Census Bureau ; 2000.
3.
3. Dawber T. The Framingham Study: The Epidemiology of Atherosclerotic Disease. Cambridge, Ma: Harvard University Press ; 1980.
4.
4. National Heart, Lung and Blood Institute. Morbidity & Mortality: 1998 Chartbook on Cardiovascular, Lung, and Blood Diseases. Rockville, Md: US Dept of Health and Human Services, National Institutes of Health ; 1998.
5.
5. Kannel W, Dawber T, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease—six year follow-up experience: the Framingham Study . Ann Intern Med. 1961;55: 33-50 .
6.
6. Doyle J, Dawber T, Kannel W, Heslin A, Kahn H. Cigarette smoking and coronary heart disease: combined experience of the Albany and Framingham studies . N Engl J Med. 1962;266: 796-801 .
7.
7. Doyle J, Dawber T, Kannel W, Kinch S, Ha K. The relationship of cigarette smoking to coronary heart disease: the second report of the combined experience of the Albany, NY, and Framingham, Ma, studies . JAMA. 1964;190: 886-890 .
8.
8. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) . Arch Intern Med. 1993;153: 154-183 .
9.
9. National Cholesterol Education Program. High Blood Cholesterol in Adults: Report of the Expert Panel on Detection, Evaluation and Treatment. Bethesda, Md: National Heart, Lung and Blood Institute ; 1988.
10.
10. National Center for Health Statistics. Health United States, 1995. Hyattsville, Md: US Dept of Health and Human Services, Public Health Service, CDC, National Center for Health Statistics ; 1995. DHHS publication (PHS) 96-1232.
11.
11. Harris D, Douglas P. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung and Blood Institute . N Engl J Med. 2000;343: 475-480 .
12.
12. Center for Drug Evaluation and Research. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs . The Federal Register1993;58: 39406-39416 .
13.
13. Kaski J, Rosano G, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson P. Cardiac syndrome X: clinical characteristics and left ventricular function . J Am Coll Cardiol. 1995;25: 807-814 .
14.
14. Kim C, Schaaf C, Maynard C, Every N. Unstable angina in the myocardial infarction triage and intervention registry (MITI): short- and long-term outcomes in men and women . Am Heart J. 2001;141: 73-77 .
15.
15. Lerner D, Kannel W. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population . Am J Cardiol. 1986;111: 383-390 .
16.
16. Mosca L, Manson J, Sutherland S, Langer R, Manolio T, Barrett-Connor E. Cardiovascular disease in women . Circulation. 1997;96: 2468-2482 .
17.
17. Heim LJ, Brunsell SC. Heart disease in women . Primary Care: Clinics in Office Practice. 2000;27: 741-766 .
18.
18. Task Force on Women's Health Issues. Women's Health: Report of the Public Health Service Task Force on Women's Health Issues. 2 vol. Washington, DC: Government Printing Office ; 1985.
19.
19. Bellanger C, Hennekens C, Rosner B, Speizer F. The Nurses' Health Study . Am J Nursing. 1978;78: 1039-1040 .
20.
20. Willett W, Hennekens C, Bain C, Rosner B, Speizer F. Cigarette smoking and non-fatal myocardial infarction in women . Am J Epidemiol. 1981;113: 575-582 .
21.
21. Myers A, Rosner B, Abbey H, et al. Smoking behavior among participants in the Nurses' Health Study . Am J Publ Health. 1987;77: 628-630 .
22.
22. Willett W, Green A, Stampfer M, et al. Relative and absolute risks of coronary heart disease among women who smoke cigarettes . N Engl J Med. 1987;317: 1303-1309 .
23.
23. Wolk A, Manson J, Stampfer M, et al. Long-term intake of dietary fiber and decreased risk of coronary heart disease among women . JAMA. 1999;281: 1998-2004 .
24.
24. Liu S, Stampfer M, Hu F, et al. Whole grain consumption and risk of coronary heart disease: results from the Nurses' Health Study . Am J Clin Nutr. 1999;70: 412-419 .
25.
25. Liu S, Willett W, Stampfer M, et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women . Am J Clin Nutr. 2000;71: 1455-1461 .
26.
26. Stampfer M, Hu F, Manson J, Rimm E, Willett W. Primary prevention of coronary heart disease in women through diet and lifestyle . N Engl J Med. 2000;343: 16-22 .
27.
27. Fiebach N, Herbert P, Stampfer M, et al. A prospective study of high blood pressure and cardiovascular disease in women . Am J Epidemiol. 1989;130: 646-654 .
28.
28. Witteman J, Willett W, Stampfer M, et al. A prospective study of nutritional factors and hypertension among US women . Circulation. 1989;80: 1320-1327 .
29.
29. Manson J, Colditz G, Stampfer M, et al. A prospective study of obesity and risk of coronary heart disease in women . N Engl J Med. 1990;322: 882-889 .
30.
30. Kawachi I, Colditz G, Stampfer M, et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women . Arch Int Med. 1994;154: 169-175 .
31.
31. Willett W, Manson J, Stampfer M, et al. Weight, weight change, and coronary heart disease in women: risk within the “normal” weight range . JAMA. 1995;273: 461-465 .
32.
32. Anonymous. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure . Arch Int Med. 1997;157: 2413-2446 .
33.
33. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study . BMJ. 1998;316: 1043-1047 .
34.
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . JAMA. 2001;285: 2486-2497 .
35.
35. Ridker P, Rifai N, Rose L, Buring J, Cook N. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events . N Engl J Med. 2002;347: 1557-1565 .
36.
36. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention . Circulation. 2003;107: 363-369 .
37.
37. Albert M, Danielson E, Rifai N, Ridker P. Effect of statin treatment on C-reactive protein levels: the pravastatin inflammation/C-reactive protein evaluation (PRINCE): a randomized trial and cohort study . JAMA. 2001;286: 64-70 .
38.
38. August P, Oparil S. Hypertension in women (commentary) . J Clin Endocrinol Metab. 1999;84: 1862-1866 .
39.
39. Burt VL, Whelton P, Roccella EJ, et al. Prevalence if hypertension in the US adult population: results of the Third National Health and Nutrition Examination Survey, 1988-1991 . Hypertension. 1995;25: 305-313 .
40.
40. Reckelhoff J. Gender differences in the regulation of blood pressure . Hypertension. 2001;37: 1199-1208 .
41.
41. Staessen J, Bulpitt C, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure . J Hum Hypertens. 1989;3: 427-433 .
42.
42. Sevre K, Lefrandt J, Nordby G, et al. Autonomic function in hypertensive and normotensive subjects: the importance of gender . Hypertension. 2001;37: 1351-1356 .
43.
43. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . JAMA. 2002;288: 2981-2997 .
44.
44. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Baseline characteristics of participants in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) . Hypertension. 2001;37: 19-27 .
45.
45. Krommal R, Hart R, Manolio T, Talbert R, Beauchamp N, Newman A. Aspirin use and incident stroke in the cardiovascular health study . Stroke. 1998;29: 887-894 .
46.
46. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial . Lancet. 1998;351: 1755-1762 .
47.
47. Iso H, Hennekens CH, Stampfer MJ, et al. Prospective study of aspirin use and risk of stroke in women . Stroke. 1999;30: 1764-1771 .
48.
48. Massie B, Shah N. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management . Am Heart J. 1997;133: 703-712 .
49.
49. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomized trial . Lancet. 1999;353: 9-13 .
50.
50. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II) . Circulation. 2001;103: 375-380 .
51.
51. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure . N Engl J Med. 1996;334: 1349-1355 .
52.
52. Packer M, Colucci W, Sackner-Bernstein J, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure . Circulation. 1996;94: 2793-2799 .
53.
53. Colucci W, Packer M, Bristow M, Gilbert E, Cohn J, Fowler M. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure . Circulation. 1996;94: 2800-2806 .
54.
54. Bristow M, Gilbert E, Abraham W, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure . Circulation. 1996;94: 2807-2816 .
55.
55. Cohn J, Fowler M, Bristow M, Group for the United States Carvedilol Heart Failure Study. Effect of carvedilol in severe chronic heart failure . JACC. 1996;27: 169A .
56.
56. Packer M, Coats A, Fowler M, et al. Effect of carvedilol on survival in severe chronic heart failure . N Engl J Med. 2001;344: 1651-1658 .
57.
57. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure . JAMA. 2000;283: 1295-1302 .
58.
58. Ghali J, Pina I, Gottlieb S, Reedwania P, Wikstrand J. Metoprolol CR/XL in female patients with heart failure . Circulation. 2002;105: 1585-1591 .
59.
59. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure . N Engl J Med. 1997;336: 525-533 .
60.
60. Rathore S, Wang Y, Kurmholz H. Sex-based differences in the effect of digoxin for the treatment of heart failure . N Engl J Med. 2002;347: 1403-1411 .
61.
61. Vittinghoff E, Shilpak M, Varosypdfurberg C, et al. Risk factors and secondary prevention in women with heart disease: the heart and estrogen/progestin study . Ann Intern Med. 2003;138: 81-89 .
